|
|
|
|
|
|
TABLE OF CONTENTS
|
October 3, 2007 NEW YORK (Reuters) - ImClone Systems Inc and Bristol-Myers Squibb Co said on Tuesday that U.S. regulators had approved a broadened label for their Erbitux drug to include survival data for its use as a single agent for advanced colorectal cancer patients who failed other drugs. The approval of the Erbitux application was based on a late-stage clinical trial involving 572 patients. "Erbitux is now the only approved biologic therapy to demonstrate improved overall survival as a single agent in patients with metastatic colorectal cancer," Martin Birkhofer, vice president of oncology global medical affairs at Bristol-Myers, said in a statement. Copyright 2008 Reuters. Click for Restrictions.
|
